^
Association details:
| Biomarker: | EGFR wild-type + ALK wild-type + ROS1 wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
82P - Preliminary analysis of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC)
Published date:
12/01/2022
Excerpt:
We planned to recruit 33 patients (pts) with stage IIIA/IIIB EGFR/ALK/ROS wild-type NSCLC. Eligible pts received 2 cycles of neoadjuvant chemoimmunotherapy (PD-1 inhibitor TIS, nab-paclitaxel, and cisplatin/carboplatin)….Of 18 pts who underwent resection,6 (33.3%) achieved pCR and 4 (22.2%) achieved MPR, resulting in an overall pathologic response rate of 55.6%. Of the 4 pts who achieved MPR, 3 had only 1% viable tumor cells in the resection specimen. The overall response rate (ORR) and disease control rate (DCR) were 88.9% (16/18) and 100 % (18/18), respectively. Both the clinical and pathological downstaging occurred in 16 of 18 pts (88.9%).
Secondary therapy:
cisplatin + albumin-bound paclitaxel; carboplatin + albumin-bound paclitaxel
Trial ID:
